XORTX Therapeutics (TSXV:XRTX) Other Net Income (Loss) : C$0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics Other Net Income (Loss)?

XORTX Therapeutics's Other Net Income (Loss) for the three months ended in Sep. 2023 was C$0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2023 was C$0.00 Mil.

XORTX Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for XORTX Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Other Net Income (Loss) Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Net Income (Loss)

Get a 7-Day Free Trial

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

XORTX Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

XORTX Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (TSXV:XRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

XRTX:USA ANUA:Germany ANUA:Germany

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.